Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
The ATAC ('Arimidex', tamoxifen, alone or in combination) adjuvant breast cancer trial: First results of the endometrial sub-protocol following 2 years of treatment
Human Reproduction, Volume 21, No. 2, Year 2006
Notification
URL copied to clipboard!
Description
Background: Tamoxifen treatment results in a doubling of the risk of endometrial cancer after 1-2 years of treatment and a quadrupling after 5 years. Anastrozole, a third-generation aromatase inhibitor, with superior efficacy to tamoxifen, may also offer tolerability benefits in terms of effects on the endometrium. Methods and results: A sub-protocol of the ATAC trial compared the incidence/type of intrauterine changes following treatment with these agents in a subgroup of patients (n = 285) from the main trial. After 2 years anastrozole treatment, endometrial thickness remained ≤ 5 mm (baseline: 3.0 mm); in patients receiving tamoxifen, endometrial thickness increased by 3.2 mm to 7.0 mm, with a similar trend in the combination group. At baseline, 26/285 patients (9.1%) had endometrial abnormalities, most commonly polyps. After 2 years the number of endometrial abnormalities appeared lower with anastrozole treatment compared with tamoxifen although these differences were not statistically significant (odds ratio: 0.44; 95% confidence interval 0.146, 1.314; P = 0.14). Most abnormalities occurred within the first year of treatment (anastrozole: 4/6; tamoxifen: 7/10; combination: 10/16; total: 21/32). Fewer patients in the anastrozole group (1.4%) required medical intervention (tamoxifen 12.5%; combination 13.6%). Conclusions: Fewer endometrial abnormalities occurred during 2 years treatment with anastrozole compared with tamoxifen although statistical significance was not reached in this sub-protocol analysis. © The Author 2005. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.
Authors & Co-Authors
Duffy, S.
United Kingdom, Leeds
St James's University Hospital
Jackson, T. L.
United Kingdom, Middlesbrough
The James Cook University Hospital
Lansdown, Mark Reginald J.
United Kingdom, Leeds
St James's University Hospital
Philips, K.
United Kingdom, Cottingham
Castle Hill Hospital
Wells, Michael
United Kingdom, Sheffield
Royal Hallamshire Hospital
Pollard, S.
United Kingdom, Leeds
Northern and Yorkshire Clinical Trials and Research Unit
Clack, G.
United Kingdom, Cambridge
Astrazeneca
Coibion, M.
Belgium, Brussels
Institut Jules Bordet
Bianco, Angelo Raffaele
Italy, Naples
Università Degli Studi Di Napoli Federico Ii
Adams, Judith Elizabeth
United Kingdom, Manchester
The University of Manchester
Baum, Michael B.
United Kingdom, London
University College London
Buzdar, Aman U.
United States, Houston
University of Texas Health Science Center at Houston
Cella, David F.
United States, Evanston
Northwestern University
Coleman, RE E.
United Kingdom, Sheffield
Weston Park Cancer Centre
Constenla, M.
Spain, Pontevedra
Hospital Montecelo
Cuzick, Jack M.
United Kingdom, London
Cancer Research uk
Distler, Wolfgang
Germany, Dresden
Medizinische Fakultät Carl Gustav Carus
Dowset, M.
United Kingdom, London
The Royal Marsden Hospital
Eastell, R.
United Kingdom, Sheffield
The University of Sheffield
Fallowfield, L. J.
United Kingdom, Brighton
University of Sussex
Forbes, John Frederick
Australia, Waratah
Newcastle Mater Misericordiae Hospital
George, William David
United Kingdom, Glasgow
Beatson West of Scotland Cancer Centre
Gray, J.
United Kingdom, Belfast
Belfast City Hospital
Guastalla, Jean Paul
France, Lyon
Le Centre Régional de Lutte Contre le Cancer Léon Bérard
Hellmund, R.
United Kingdom, Cambridge
Astrazeneca
Hoctin-Boes, G.
United Kingdom, Cambridge
Astrazeneca
Houghton, Joan
United Kingdom, London
University College London
Williams, Norman R.
United Kingdom, London
University College London
Howell, Anthony H.
United Kingdom, Manchester
The Christie Nhs Foundation Trust
Klijn, J. C.M.
Netherlands, Rotterdam
Erasmus Mc
Locker, G. Y.
United States, Chicago
Northwestern University Feinberg School of Medicine
Mackey, John R.
Canada, Edmonton
Cross Cancer Institute
Mansel, Robert E.
United Kingdom, Cardiff
Cardiff University
Nabholtz, Jean Marc A.
France, Levallois-perret
Hartman Oncology Institute
Naglkalnai, T.
Hungary, Budapest
Uzsoki Municipal Hospital
Nicolucci, Antonio
Italy, Santa Maria Imbaro
Consorzio Mario Negri Sud
Italy, Milan
Istituto Di Ricerche Farmacologiche Mario Negri
Nylen, U.
Sweden, Stockholm
Karolinska Universitetssjukhuset
Sainsbury, R.
United Kingdom, London
University College London
Sapunar, F.
United Kingdom, Cambridge
Astrazeneca
United Kingdom, Edinburgh
Isd Cancer Clinical Trials Team
Suarez-Mendez, V. J.
United Kingdom, Cambridge
Astrazeneca
United Kingdom, Edinburgh
Isd Cancer Clinical Trials Team
Tobias, Jeffrey S.
United Kingdom, London
Middlesex Hospital London
Friedlander, M. L.
Australia, Sydney
Oncology day Centre
Richardson, Gary Edward
Australia, Clayton
Monash Medical Centre
Makar, A.
Belgium, Antwerpen
Algemeen Ziekenhuis Middelheim, Antwerpen
Neven, Patrick
Belgium, Brussels
St Jan Ziekenhuis
Mention, J.
France, Amiens
Centre de Gynecologie-obstetrique
Distler, D. W.
Germany, Dresden
Universitätsklinikum Carl Gustav Carus Dresden
Eiermann, Wolfgang
Germany, Munich
Frauenklinik Vom Roten Kreuz
Mouritis, M.
Netherlands, Groningen
Afdling Verloskunde en Gynaecologie
Wamsteker,
Netherlands, Hoofddorp
Spaarne Hospital
Campos, O.
Portugal, Coimbra
Maternidade Bissaya Barreto
Candeias, O. Rolao
Portugal, Porto
Sao Joao Hospital
Landers, G.
South Africa, Durban
Parklands Hospital
Llombart-Cussac, Antonio C.
Spain, Valencia
Instituto Valenciano de Oncologia
Menjon, S.
Spain, Granada
Complejo Hospitalario Universitario de Granada
Repolle´s, M.
Spain, Madrid
Hospital Universitario Ramón y Cajal
Lindahl, B.
Sweden, Lund
Skånes Universitetssjukhus
Ingvar, C.
Sweden, Lund
Skånes Universitetssjukhus
Bharbra, K.
United Kingdom, Huddersfield
Huddersfield Royal Infirmary
Bjornsson, S.
United Kingdom, Glasgow
Victoria Infirmary
Charnock, F.
United Kingdom, Oxford
Oxford University Hospitals Nhs Foundation Trust
Cutner, A.
United Kingdom, London
Elizabeth Garrett Anderson and Obstetric Hospital
De Bono, M.
United Kingdom, Halifax
Royal Halifax Infirmary
Evans-Jones, J.
United Kingdom, Colchester
Colchester General Infirmary
Glass, M. R.
United Kingdom, Leeds
Leeds General Infirmary
Holt, S.
United Kingdom, Llanelli
Prince Philip Hospital
Jones, Allison Louise
United Kingdom, London
The Royal Free Hospital
Kremer,
United Kingdom, Wakefield
Pinderfields General Hospital
O'Donovan, Peter
United Kingdom, Bradford
Bradford Royal Infirmary
Omara-Boto, T. Adie
United Kingdom, Colchester
East Suffolk and North Essex Nhs Foundation Trust
Onwude, J.
United Kingdom, Chelmsford
St. John's Hospital
Phillips, K.
United Kingdom, Cottingham
Castle Hill Hospital
Price, Joanne J.
United Kingdom, Belfast
Belfast Health and Social Care Trust
Samtaney, N.
United Kingdom, Keighley
Airedale General Hospital
Seif, Mourad W.
United Kingdom, London
St Mary's Hospital
Doe, A.
United Kingdom, Edinburgh
Isd Cancer Clinical Trials Team
Foster, E.
United Kingdom, Cambridge
Astrazeneca
Woolas, R.
United Kingdom, London
St Mary's Hospital
Buyse, Marc E.
Belgium, Louvain-la-neuve
International Drug Development Institute, Charleroi
Wale, C.
United Kingdom, London
Cancer Research uk
Margolese, R.
Canada, Montreal
Sir Mortimer B. Davis Jewish General Hospital
Body, Jean–Jacques
Belgium, Brussels
Institut Jules Bordet
Statistics
Citations: 82
Authors: 82
Affiliations: 69
Identifiers
Doi:
10.1093/humrep/dei322
ISSN:
02681161
Research Areas
Cancer
Study Design
Randomised Control Trial
Cohort Study
Case-Control Study